ライフサイエンスコーパス: probenecid

1 5-1 mg/kg per dose, every 2-3 weeks, without probenecid).

2 om a "chemical double" knockout (Oat3KO plus probenecid).

3 x shedding (from 6 h), which were blocked by probenecid.

4 t had been preceded by prophylaxis with oral probenecid.

5 hout reducing sensitivity to cannabidiol and probenecid.

6 nduced by chronic administration of MPTP and probenecid.

7 ersed by cotreatment with the OAT6 inhibitor probenecid.

8 at different sites: 2-APB, cannabidiol, and probenecid.

9 Delta(9)-tetrahydrocannabiorcol (C16) and by probenecid.

10 n an autoinhibited state and in complex with probenecid.

11 e addition of salicin and TAS2R16 antagonist probenecid.

12 under the influence of allosteric control by probenecid.

13 ing estrone, lipoic acid, valproic acid, and probenecid.

14 e in therapeutic screening of riboflavin and probenecid.

15 or 750 mg four times daily) with and without probenecid.

16 fibroblasts treated with the Panx1 blocker, probenecid.

17 nt, yet reversible manner in the presence of probenecid.

18 , and by pannexin blockers carbenoxolone and probenecid.

19 exin1 (Panx1) mimetic peptide (10)Panx1, and probenecid.

20 e preparation of an aza analogue of the drug probenecid.

21 urate-lowering drugs include allopurinol and probenecid.

22 ges pretreated with the pannexin-1 inhibitor probenecid.

23 by administration of non-radioactive ALA and probenecid.

24 thiocyanatostilbene-2,2'-disulfonic acid and probenecid.

25 .v. infusion with VPA alone or with VPA plus probenecid.

26 f the efflux transporters are inhibitable by probenecid.

27 ically slowed and overshoot was abolished by probenecid.

28 fects were reduced by the pannexin inhibitor probenecid.

29 nced with a 10-day course of amoxicillin and probenecid.

30 ed with IFN-gamma that was also inhibited by probenecid.

31 Probenecid (0.1 mM) or novobiocin (0.1 mM) added to the

32 Probenecid (1 mM), alpha-cyano-4-hydroxycinnamic acid (4

33 ely 0.25 muM) and pannexin channel inhibitor probenecid (10 mg/kg, IC50 approximately 11.7 muM), we s

34 or, % inhibition): 1.5 mM alphaKG, 80%; 1 mM probenecid, 100%; 1 mM piroxicam, 100%; 1 mM octanoate,

35 In contrast, a high intravenous dose of probenecid (250 mg/kg) only slightly inhibited SD elicit

36 Probenecid, a classic pharmacological agent for gout, ha

37 ansport of cGMP from colorectal epithelia by probenecid, a mechanism validated by studies in cultured

38 ockage of the tubular secretion pathway with probenecid, a necessary condition for establishment of c

39 C16 and probenecid act in concert to stimulate TRPV2 responses i

40 inhibitors benzbromarone, sulfinpyrazone and probenecid all inhibit verinurad binding via a competiti

41 PTA analysis shows probenecid allows a fourfold increase in MIC cover.

42 Probenecid also inhibited the regulatory volume decrease

43 The cytotoxic effects were fully reversed by probenecid (an OAT1 inhibitor) and partially reversed by

44 sma concentrations of non-radioactive ALA or probenecid (an organic anion transport inhibitor) and, t

45 of this study was to examine the effects of probenecid, an inhibitor of organic anion transport, on

46 Indeed, treatment of humans with probenecid, an OAT-inhibitor used to treat gout, elevate

47 s significantly inhibited in the presence of probenecid, an organic anion transporter inhibitor.

48 nction, or in the presence or the absence of probenecid, an organic ion transport inhibitor that appe

49 loromercuriphenylsulfonate and by the anions probenecid and 4,4'-diisothiocyanostilbene-2,2'-disulfon

50 The syntheses of 13 C-labeled probenecid and bioisosteres of ataluren as well as the u

51 To minimize nephrotoxicity, oral probenecid and intravenous hydration with normal saline

52 ministered and concomitant administration of probenecid and saline hydration appeared to minimize dru

53 ked down or inhibited by two PANX1 blockers, Probenecid and Spironolactone.

54 tly by multiple Panx inhibitors (mefloquine, probenecid, and (10)Panx1), ectonucleotidase (apyrase),

55 isothiocyanatostilbene-2,2'-disulfonic acid, probenecid, and sulfinpyrazone, inhibitors of MRP1 and M

56 of the pannexin 1 blockers carbenoxolone and probenecid, and the HlyA-induced ATP release was found t

57 ular aqueous procaine penicillin G plus oral probenecid (APPG-P) were evaluated.

58 ular aqueous procaine penicillin G plus oral probenecid (APPG-P).

59 Since Panx1 inhibitors such as probenecid are already clinically tested in different se

60 Using probenecid as an initial lead compound, we designed a co

61 Treatment of female mice with low dose of probenecid as well as with the PTGS inhibitor indomethac

62 The drug-bound state reveals two probenecid binding sites that suggest a dynamic interpla

63 At the CP, verapamil and probenecid (but not indomethacin) significantly increase

64 for some inhibitors (up to 4-fold), such as probenecid, but not for others (an inhibitor-dependent e

65 of uric acid-lowering agents allopurinol and probenecid can lower blood pressure in adolescents.

66 Probenecid co-infusion elevated the ICC-to-ECF concentra

67 Probenecid co-infusion elevated VPA concentration in the

68 Riboflavin and probenecid co-treatment provides an additional small ben

69 was no difference between the timepoints in probenecid concentrations.

70 The ABCC4 inhibitor probenecid demonstrated effective blocking of ovulation

71 t, inhibition of cyclic nucleotide efflux by probenecid did not affect the background Na(+) conductan

72 Co-infusion of probenecid did not have a significant effect on VPA effl

73 Enhanced treatment with amoxicillin and probenecid did not improve the outcomes.

74 Probenecid did not inhibit folate binding to FR, but inh

75 protein inhibitors, such as indomethacin and probenecid, effectively increased the accumulation of EG

76 hibition, for example by the uricosuric drug probenecid, elevates circulating bilirubin glucuronide a

77 n penicillin-V alone and in combination with probenecid for serum total and free penicillin-V concent

78 vels of urate lowering, the uricosuric agent probenecid had no effect on endothelial function.

79 observed for inhibition of PAH transport by probenecid in renal basolateral membrane vesicles (5.2-f

80 In contrast, probenecid, in a concentration-dependent manner, inhibit

81 Transient reactions to probenecid, including mild to moderate constitutional sy

82 date putamen 3-5 times, and indomethacin and probenecid increased accumulation in ependyma 4-5 times.

83 Perfusion of 1-20 mM probenecid increased dose-dependently the dialysate leve

84 How probenecid inhibits SD deserves further investigation be

85 Probenecid is a promising therapeutic candidate for RTD

86 Panx1 blockade using probenecid markedly inhibits leukocyte transmigration, a

87 Therefore, probenecid may inhibit C. trachomatis growth by an as ye

88 apnia, we have examined the possibility that probenecid may inhibit SD through extracellular acidific

89 rall cAMP response of three MRP4 inhibitors, probenecid, MK571, and ceefourin-1 in PDAC in vitro mode

90 l-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/probenecid mouse model was used to examine the changes i

91 The organic anions probenecid, octanoate, and alpha-ketoglutarate reduced o

92 volunteers to characterise the influence of probenecid on penicillin-V pharmacokinetics and estimate

93 openem followed by oral sulopenem etzadroxil/probenecid or 5 days of IV ertapenem followed by oral ci

94 blocking pannexin/gap junction channels with probenecid or carbenoxolone significantly reduced extern

95 , whereas it was impaired in the presence of probenecid or carbenoxolone.

96 accumulation of adenosine was not blocked by probenecid or GMP, suggesting that neither extracellular

97 Release was blocked by carbenoxolone, probenecid or peptide (10)panx, implicating pannexin cha

98 ve mass treatment (SMT) with oral ampicillin-probenecid or tetracycline was then given to registered

99 cking pannexin-1 hemichannels with (10)Panx, probenecid, or carbenoxolone but not when connexin hemic

100 We show probenecid potently blocks SARS-CoV-2 replication in mam

101 he selective activation of TRPV2 channels by probenecid promoted the sADP to generate a plateau poten

102 Before treatment with probenecid, RBF was linearly related to hippuran clearan

103 n after drug administration, confirming that probenecid readily penetrated the central nervous system

104 Although the binding for probenecid remains elusive, C16 associates within the va

105 als, such as ataluren, celecoxib, flavoxate, probenecid, repaglinide, and tamibarotene.

106 Inhibition of MRP4 in HTM cells by MK571 or probenecid resulted in cell shape changes and decreases

107 Depletion of PNX1 by siRNA or inhibition by probenecid resulted in significant blocking of extracell

108 The resulting CHOhOAT cells showed probenecid-sensitive and pH-dependent uptake of p-aminoh

109 t LTC4 is secreted by normal mast cells by a probenecid-sensitive mechanism that is independent of MR

110 Probenecid-sensitive transport of EC cGMP between AC fis

111 e-fractionated poly(A)+ RNA and screened for probenecid-sensitive transport of p-aminohippurate (PAH)

112 Probenecid-sensitive transport of the NAC-Hg(2+) conjuga

113 us laevis oocytes expressing hOAT1 supported probenecid-sensitive uptake of [(3)H]p-aminohippurate (K

114 n transporter 1 (rROAT1) mediated saturable, probenecid-sensitive uptake of cidofovir, adefovir, and

115 (203)Hg-uptake studies showed probenecid-sensitive uptake of mercury-thiol conjugates

116 p-aminohippurate (PAH) uptake was saturable, probenecid-sensitive, and inhibited by a wide range of o

117 hemichannels with CO(2)-saturated buffer or probenecid significantly reduced cell-cell signalling be

118 Sulopenem etzadroxil/probenecid (sulopenem) is an oral thiopenem antibiotic a

119 nsport inhibitors MK571, sulfinpyrazone, and probenecid, supporting a role for the MRP transporters i

120 inhibited by the pannexin 1 channel blocker probenecid, supporting a role of pannexin 1 in inflammas

121 broad-spectrum Panx1 blockers, mefloquine or probenecid, suppressed ATP release and reduced withdrawa

122 -stimulated by the organic substrates MK571, probenecid, taurocholic acid, estrone sulfate, and bromo

123 In contrast, sodium 4-phenylbutyrate and probenecid, the latter a uricosuric drug used clinically

124 SD was markedly reduced by perfusion of 5 mM probenecid through the microdialysis probe.

125 ta support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

126 ment of rodents with the OAT-inhibiting drug probenecid to identify potential drug-metabolite interac

127 sured twice, before and after treatment with probenecid, to verify that RBF is not affected.

128 50% (P=0.03) to 2.01+/-0.08 mL/min/100 g in probenecid-treated rats.

129 gle-injection clearance method in normal and probenecid-treated rats.

130 Probenecid treatment significantly reduced hippuran clea

131 and placebo for the first study and 1000 mg probenecid versus placebo in the second study.

132 nd possible therapeutic benefit conferred by probenecid warrants further investigation.

133 Probenecid was administered either directly through the

134 openem followed by oral sulopenem-etzadroxil/probenecid was not noninferior to ertapenem followed by

135 tive to inhibition by bromosulfophthalein or probenecid was observed for taurocholate, estrone sulfat

136 Addition of probenecid was safe and well tolerated.

137 and free concentrations of penicillin-V and probenecid were measured at two timepoints.

138 Moreover, probenecid, which blocks the export of cAMP, inhibited t

139 Treatment with carbenoxolone and probenecid, which directly and specifically block Panx1

140 e patient received intravenous hydration and probenecid with the infusions to reduce the nephrotoxici

141 rug compounds (indomethacin, gemfibrozil and probenecid), with high efficiency (s >100) is also descr

142 in the US, we therefore investigated whether probenecid would have a direct effect on Chlamydia trach